Preclinical evaluation of a high-affinity 18F-trifluoroborate octreotate derivative for somatostatin receptor imaging

Journal of Nuclear Medicine

Volumn 55, Issue 9, 2014, Pages 1499-1505

  Liu, Zhibo ^a   Pourghiasian, Maral ^b   Bénard, François ^b   Pan, Jinhe ^b   Lin, Kuo Shyan ^b   Perrin, David M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

1 step 18F labeling; 18F BF3; Octreotate; Octreotide; Positron emission tomography; Somatostatin receptor

Indexed keywords

FLUORINE; FLUORINE 18; N PROPARGYL N,N DIMETHYL AMMONIOMETHYLTRIFLUOROBORATE F 18; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TRIFLUOROBORATE OCTREOTATE F 18 DERIVATIVE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; ION EXCHANGE; ISOTOPE LABELING; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOCHEMISTRY; RAT; TISSUE DISTRIBUTION; 1-STEP 18F-LABELING; 18F-BF3; ANIMAL; EXPERIMENTAL NEOPLASM; OCTREOTATE; SCID MOUSE; SCINTISCANNING;

1-STEP 18F-LABELING; 18F-BF3; OCTREOTATE; OCTREOTIDE; POSITRON EMISSION TOMOGRAPHY; SOMATOSTATIN RECEPTOR;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUORINE RADIOISOTOPES; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION;

EID: 84907010619     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.137836     Document Type: Article

References (37)

1. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2010;40:78-88.
2. Breeman WAP, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptormediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421-1429.
3. Ginj M, Schmitt JS, Chen JH, et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol. 2006;13:1081-1090.
4. Antunes P, Ginj M, Walter MA, et al. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. Bioconjug Chem. 2007;18: 84-92.
5. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
6. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with In-111- pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf). 2003;59:565-573.
7. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of Ga-68-DOTATOC PET and In-111-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
8. Storch D, Behe M, Walter MA, et al. Evaluation of [99mTc/EDDA/HYNIC0] octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med. 2005;46:1561-1569.
9. Virgolini I, Leimer M, Handmaker H, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58:1850-1859.
10. Gabriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708-716.
11. Sprague JE, Peng YJ, Sun XK, et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10:8674-8682.
12. Gabriel M, Decristoforo C, Kendler D, et al. Ga-68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
13. Guo Y, Ferdani R, Anderson CJ. Preparation and biological evaluation of Cu-64 labeled tyr3-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator. Bioconjug Chem. 2012;23:1470-1477.
14. Wester HJ, Schottelius M, Scheidhauer K, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel F-18-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging. 2003;30: 117-122.
15. Poethko T, Schottelius M, Thumshim G, et al. Two-step methodology for highyield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.
16. Leyton J, Iddon L, Perumal M, et al. Targeting somatostatin receptors: preclinical evaluation of novel F-18-fluoroethyltriazole-tyr3-octreotate analogs for PET. J Nucl Med. 2011;52:1441-1448.
17. Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053-1056.
18. Kayani I, Conry BG, Groves AM, et al. A comparison of Ga-68-DOTATATE and F-18-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50: 1927-1932.
19. Poeppel TD, Binse I, Petersenn S, et al. Ga-68-DOTATOC versus Ga-68- DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864-1870.
20. Banerjee SR, Pomper MG. Clinical applications of gallium-68. Appl Radiat Isot. 2013;76:2-13.
21. Laforest R, Liu X. Image quality with non-standard nuclides in PET. Q J Nucl Med Mol Imaging. 2008;52:151-158.
22. Kemerink GJ, Visser MGW, Franssen R, et al. Effect of the positron range of F-18, Ga-68 and I-124 on PET/CT in lung-equivalent materials. Eur J Nucl Med Mol Imaging. 2011;38:940-948.
23. Zhan C-G, Dixon DA. Hydration of the fluoride anion: structures and absolute hydration free energy from first-principles electronic structure calculations. J Phys Chem A. 2004;108:2020-2029.
24. Chin FT, Shen B, Liu SL, et al. First experience with clinical-grade F-18 FPP (RGD)(2): an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol. 2012;14:88-95.
25. Cai H, Conti PS. RGD-based PET tracers for imaging receptor integrin alphavbeta3 expression. J Labelled Comp Radiopharm. 2013;56:264-279.
26. Wängler C, Waser B, Alke A, et al. One-step F-18-labeling of carbohydrateconjugated octreotate-derivatives containing a silicon-fluoride-acceptor (SiFA): in vitro and in vivo evaluation as tumor imaging agents for positron emission tomography (PET). Bioconjug Chem. 2010;21:2289-2296.
27. Laverman P, D'Souza CA, Eek A, et al. Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol. 2012;33:427-434.
28. Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with F-18-fluorine. J Nucl Med. 2010;51:454-461.
29. Liu Z, Li Y, Lozada J, et al. Rapid, one-step, high yielding 18F-labeling of an aryltrifluoroborate bioconjugate by isotope exchange at very high specific activity. J Labelled Comp Radiopharm. 2012;14:491-497.
30. Liu Z, Li Y, Lozada J, et al. Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging. Nucl Med Biol. 2013;40:841-849.
31. Liu Z, Li Y, Lozada J, et al. Stoichiometric leverage: rapid 18F-aryltrifluoroborate radiosynthesis at high specific activity for click conjugation. Angew Chem Int Ed. 2013;52:2305-2307.
32. Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ. In vitro and in vivo evaluation of Cu-64-TETA-Tyr3-octreotate: a new somatostatin analog with improved target tissue uptake. Nucl Med Biol. 1999;26:267-273.
33. Matteson DS, Majumdar D. Iodomethaneboronic esters and aminomethane boronic esters. J Organomet Chem. 1979;170:259-264.
34. Eberl S, Eriksson T, Svedberg O, et al. High beam current operation of a PETtrace™ cyclotron for 18F- production. Appl Radiat Isot. 2012;70:922-930.
35. Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481-1489.
36. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
37. Vallabhajosula S, Moyer BR, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med. 1996;37:1016-1022.